Effects of the H 2 -Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir With or Without Tenofovir in HIV-Infected Patients
Jenny Zhang, Yaoshi Wu(Bristol-Myers Squibb (Germany)), Richard Bertz(Bristol-Myers Squibb (Germany)), Michael Child, Angela D. M. Kashuba(University of North Carolina at Chapel Hill), Pablo Tebas(University of Pennsylvania), Zhu Li(Zhejiang Chinese Medical University), Xiaodong Wang(Baoding People's Hospital), Ellen Chung(Bristol-Myers Squibb (Germany)), Marta Boffito(Chelsea and Westminster Hospital NHS Foundation Trust), Kristine B. Patterson(University of North Carolina at Chapel Hill), Lisa Mahnke(Merck Serono S.p.A. (Italy))
Cited by 4
Related Papers
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
|Science Translational Medicine|2011|352